Edison Investment Research - Amarantus BioScience (AMBS) QuickView: Expanding into regenerative medicine

Report

Edison Investment Research

QuickView: Expanding into regenerative medicine

Amarantus entered into an option agreement with Lonza to acquire its engineered skin substitute (ESS) platform for the treatment of severe burns. It plans to start a 10-pt Phase I/II study in Q215, which could lead to launch by 2018, in a c $500m US severe burn market. The firm also plans to launch LymPro as a laboratory-developed test for Alzheimerâ€™s disease (AD) in Q414. MANF and Eltoprazine also provide value driver opportunities.

21/11/2014 2 EN

Underlying

Amarantus BioScience

See profile

United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Initiation: Building up therapeutics assets

Amarantus has acquired several pre-commercial therapeutic assets in recent years, and intends to create value by furthering their development before out-licensing or commercialising them. The firm recently acquired ESS-W, which can shorten the time needed to treat severe burns. Eltoprazine aims to reduce involuntary movements associated with long-term levodopa therapy in Parkinsonâ€™s disease. These candidates provide long-term potential, and drive our $76m rNPV.

July 27, 2015 July 27, 2015 12 EN

Edison Investment Research

QuickView: Potential of LymPro indicated

Amarantus presented data of its blood-based diagnostic test for Alzheimerâ€™s disease (AD), LymPro, at the Alzheimerâ€™s Association International Conference (AAIC). Data from a 41-patient trial with an optimised test showed a specificity of 81% and a sensitivity of 73%. Commercial launch of LymPro as a laboratory-developed test remains on track for H214. MANF has also started formal preclinical testing and could begin clinical development in 2015. Eltoprazine is expected to start a Phase IIb trial in the coming months.

August 18, 2014 August 18, 2014 2 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Expanding into regenerative medicine

Initiation: Building up therapeutics assets

QuickView: Potential of LymPro indicated

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe